The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

As the government continues its search for a new Drugs Controller General of India (DCGI), it has decided to extend the ...